• Tuberculosis and Respiratory Diseases
• /
• 제77권4호
• /
• pp.161-166
• /
• 2014

Since tuberculosis (TB) remains a major global health concern and the incidence of multi-drug resistant (MDR)-TB is increasing globally, new modalities for the detection of TB and drug resistant TB are needed to improve TB control. The Xpert MTB/RIF test can be a valuable new tool for early detection of TB and rifampicin resistance, with a high sensitivity and specificity. Late-generation fluoroquinolones, levofloxacin, and moxifloxacin, which are the principal drugs for the treatment of MDR-TB, show equally high efficacy and safety. Systemic steroids may reduce the overall TB mortality attributable to all forms of TB across all organ systems, although inhaled corticosteroids can increase the risk of TB development. Although fixed dose combinations were expected to reduce the risk of drug resistance and increase drug compliance, a recent meta-analysis found that they might actually increase the risk of relapse and treatment failure. Regarding treatment duration, patients with cavitation and culture positivity at 2 months of TB treatment may require more than 6 months of standard treatment. New anti-TB drugs, such as linezolid, bedaquiline, and delamanid, could improve the outcomes in drug-resistant TB. Nontuberculous mycobacterial lung disease has typical clinical and immunological phenotypes. Mycobacterial genotyping may predict disease progression, and whole genome sequencing may reveal the transmission of Mycobacterium abscessus. In refractory Mycobacterium avium complex lung disease, a moxifloxacin-containing regimen was expected to improve the treatment outcome.

• 대한전기학회논문지:시스템및제어부문D
• /
• 제54권4호
• /
• pp.259-266
• /
• 2005

This paper presents a therapy that uses a constant drug dosage for leading HIV-infected patient to LTNP (Long-Term Non-Progressor). Based on analysis of CTLp (Cytotoxic T Lymphocyte precursor) concentration at equilibrium point and its bifurcation, we found the therapy with a drug whose efficacy is less than a certain level brings higher CTLp concentration at the equilibrium point. We observed a treatment with constant drug dosage whose efficacy is less than full treatment may lead HIV-infected patient to LTNP. It turns out that the treatment whose efficacy is less than full treatment is better in the point of performance on controllability.

• 한국사회복지학
• /
• 제69권3호
• /
• pp.165-191
• /
• 2017

본 연구는 국내 약물사용자의 치료서비스 이용 의도에 대한 주요 예측요인을 규명하는 데 목적이 있다. 건강서비스이용행동모형에 계획행동이론을 수렴한 확장된 건강서비스이용행동모형을 이론적 틀로 하여, 약물사용자의 개인 특성 요인(선행, 가능, 욕구요인)과 약물중독 치료서비스 이용에 대한 태도, 주관적 규범, 지각된 행동통제감이 약물중독 치료서비스 이용 의도에 미치는 영향을 분석하였다. 분석결과, 약물사용자의 개인 특성 중 치료서비스 이용 의도에 직 간접적으로 유의한 영향을 미치는 요인은 선행요인 중 성별, 과거치료경험, 그리고 욕구요인 중 정신과적 진단, 불안 우울, 약물남용심각도로 나타났다. 계획행동이론의 설명 요인 중 치료서비스 이용 의도에 통계적으로 유의한 영향을 미치는 요인은 주관적 규범과 지각된 행동통제감으로 분석되었다. 본 연구결과를 통해 약물사용자의 약물중독 치료서비스 이용 증진을 위하여 여성에 대한 고려, 긍정적 치료 노출 확대, 치료서비스에 대한 주관적 규범 및 지각된 행동통제감 강화 등의 노력이 필요함을 확인하였다.

• 한국콘텐츠학회논문지
• /
• 제10권4호
• /
• pp.348-358
• /
• 2010

본 연구에서는 마약류 사용사범에 대한 설문조사를 토대로 교정처우의 개선방안에 대한 합리적인 대안을 제시하고자 하였다. 현재 교도소 내에서의 마약류 범죄자들에 대한 처우가 장래의 재범방지 및 교화개선에 효과적으로 기능하지 못한다는 가정 하에, 부정적 영향을 미치는 주된 요인들이 무엇인지를 알아보았다. 수용자들은 현재 실시되고 있는 프로그램을 신뢰하지 않았으며, 제공되는 처우가 재범방지 및 재사회화에 긍정적인 영향을 미치지 않는다고 보았다. 담당직원의 관심이 부족하다고 판단하는 재소자가 전체의 43.4%로 프로그램의 개선 뿐 아니라 담당직원의 수용자에 대한 의식개선도 필요하다는 것을 알 수 있다. 이에 더하여 강의와 주입식 진행에 치우친 처우프로그램들을 참여나 자발적인 활동을 포함하는 방식으로 개선할 필요가 있음과 시청각 자료뿐만 아니라 다양한 실험 또는 체험 위주의 프로그램 등도 요구되고 있음을 알 수 있었다. 유의수준 $\alpha$=0.05 하에서 재교육 프로그램의 만족도에 따른 마약류 사용 중단가능성에는 차이가 있다고 할 수 있는 것으로 가설이 검증되었으며, 회귀분석 결과 재교육 프로그램이 재범 방지에 충분한 역할을 하지 못하고 있다는 충분한 근거가 있는 것으로 판단되었다.

• Journal of Pharmaceutical Investigation
• /
• 제41권1호
• /
• pp.37-43
• /
• 2011

Urinary steroid levels were investigated in the treatment of CKD-501, a new anti-diabetic drug candidate. CKD-501 was administered orally at the dosage of 1, 2, 4 mg/day for 7 days to normal men (n=18). Urine was collected before, during and after stopping the drug administration and the urinary level of androgen, estrogen, progestin and corticoids were quantified using GC-MS (gas chromatography-mass spectrometry). Only urinary corticosteroid and an androgen, DHEA levels among all the analyzed steroids, have been found to increase progressively, reaching significant levels on the last day of drug treatment and later declined after the drug treatment is withdrawn. Therefore, it was thought that an increase in the urinary corticoid and DHEA levels could be a characteristic of CKD-501, since it prominently acts on the glucose sensitivity and suppresses the triglyceride levels. In conclusion, it was found that CKD-501, an anti-diabetic drug candidate, affects the glucocorticoid and DHEA levels and it plays a crucial role in glucose homeostasis.

• Archives of Pharmacal Research
• /
• 제25권5호
• /
• pp.718-723
• /
• 2002

CKD-602 (7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin) is a recently-developed synthetic camptothecin analogue and currently under clinical development by Chong Kun Dang Pharm (Seoul, Korea). CKD-602 showed potent topoisomerase inhibitory activity in vitro and broad antitumor activity against various human tumor cells in vitro and in vivo in animal models. This study describes the pharmacodynamics of the immediate and delayed cytotoxicity induced by CKD-602 in a human colorectal adenocarcinoma cell line, HT-29, and its intracellular drug accumulation by HPLC. The present study was designed to address whether the higher activity of CKD-602 with prolonged exposure is due to delayed exhibition of cytotoxicity and/or an accumulation of anti proliferative effect on continuous drug exposure. The drug uptake study was performed to determine whether the delayed cytotoxicity is due to a slow drug accumulation in cells. CKD-602 produced a cytotoxicity that was exhibited immediately after treatment (immediate effect) and after treatment had been terminated (delayed effect). Both the immediate and delayed effects of CKD-602 showed a time dependent decrease in 4IC_{50}$ values. Drug uptake was biphasic and the second equilibrium level was obtained as early as at 24hr, indicating that the cumulative and delayed antitumor effects of CKD-602 were not due to slow drug uptake. On the other hand, CKD-602 treatment was sufficient to induce delayed cytotoxicity after 4hr, however, longer treatment (＞24hr) enhanced its cytotoxicity due to the intracellular accumulation of the drug, which requires 24hr to reach maximum equilibrium concentration. In addition, $C^n$$\times$T=h analysis (n=0.481) indicated that increased exposure times may contribute more to the overall antitumor activity of CKD-602 than drug concentration. Additional studies to determine the details of the intracellular uptake kinetics (e.g., concentration dependency and retention studies) are needed in order to identify the optimal treatment schedules for the successful clinical development of CKD-602.

• 전기학회논문지
• /
• 제56권1호
• /
• pp.174-182
• /
• 2007

In this paper, we study the influence of infection ratio on gradual reduction of drug dose for the five state HIV infection model that explicitly includes the population of the virus. We first compute all equilibrium points of the model and investigate the stabilities of them. As a result, a bifurcation diagram is obtained which shows a change in the equilibrium points, or in their stability properties, as the drug effect $\eta$ is varied from 0 to 1(alternatively, drug dose is changed from 1 to 0). Based on the bifurcation diagram, we show that the gradual reduction of drug dose can be applied for the treatment of AIDS patients. Moreover, we analyze the influence of the variation of infection ratio on the gradual reduction treatment. Computer simulation results are also presented to validate the proposed results.

• 제어로봇시스템학회논문지
• /
• 제10권6호
• /
• pp.475-486
• /
• 2004

The interaction of HIV and human immune system was studied in the perspective of dynamics. We summarized the recent researches on drug scheduling using optimal control theory for HIV treatment. The drug treatment to make immune system to work properly is investigated based on mathematical models including memory CTLp. In the simulation results, it was verified that stopping medication after a certain period of treatment can lead a patient to be cured naturally by one s immune system. Also, we summarized and categorized the advantages and disadvantages of each HIV drug scheduling method. In conclusion, model-based predictive control is more efficient for making decision of drug dose than other methods, when there exist uncertainties on model parameters or state variables.

• Biomolecules & Therapeutics
• /
• 제31권1호
• /
• pp.16-26
• /
• 2023

Diabetes is an untreatable metabolic disorder characterized by alteration in blood sugar homeostasis, with submucosal insulin therapy being the primary treatment option. This route of drug administration is attributed to low patient comfort due to the risk of pain, distress, and local inflammation/infections. Nanoparticles have indeed been suggested as insulin carriers to allow the drug to be administered via less invasive routes other than injection, such as orally or nasally. The organic-based nanoparticles can be derived from various organic materials (for instance, polysaccharides, lipids, and so on) and thus are prevalently used to enhance the physical and chemical consistency of loaded bioactive compounds (drug) and thus their bioavailability. This review presents various forms of organic nanoparticles (for example, chitosan, dextron, gums, nanoemulsion, alginate, and so on) for enhanced hypoglycemic drug delivery relative to traditional therapies.

• 의료법학
• /
• 제12권1호
• /
• pp.257-285
• /
• 2011

This thesis has studied about the legal characteristic of injection of the trial drug, the position of the pharmaceutical firm as a contractor of the clinical trial, the possibility of compulsory performance of consistent injection of the trial drug, and the damage claim caused in the process of the clinical trial from the viewpoint of protecting the trial subject in the clinical trial. According to court's judgement in the United States, the lawsuit of the trial subject, although the trial subject had expected consistent injections, was dismissed because there was no direct contract between pharmaceutical and trial subject. However, Helsinki Declaration prescribe the medical research as follows. 'All patients who participated in the research should be able to use the best precaution, diagnosis, and treatment proved by the final outcome of the research'. The trial subject is entitled to demand only the pharmaceutical firm which developed and provided the trial drug, and the pharmaceutical firm has the obligation to supply the trial drug to the trial subject. Therefore, it would be not enough to protect the trial subject if the pharmaceutical firm which makes the trial drug is ruled out. In addition, especially, in case the trial drug has a constant effect with the aim of treatment, if the injection of the trial drug is suddenly stopped, the trial subject would not have the benefit of treatment by the trial drug. In this case, the best remedy against the damage is to urge a constant injection of the trial drug. Thus, in certain case, it is reasonable to consider that the pharmaceutical firm has the obligation to supply the trial drug to the trial subject constantly, and it is also necessary to compel it through effective means in case the pharmaceutical firm do not fulfill its obligation to supply the trial drug. However, as an essential prerequisite for the assertion mentioned above, it should be judged under the principle of good faith considering the concrete situation, that is, what roles the pharmaceutical firm has played.